17/08/2010 Dr. Montalban opinion about Salvitex on the market 17/08/2010 Chief of Clinical Neuroimmunology at Vall d'Hebron Research Institute (VHIR), Dr. Xavier Montalban, talks about the green light from the health authorities to market Sativex in Spain, a drug derived from cannabis for the treatment of spasticity in multiple sclerosis patients. Chief of Clinical Neuroimmunology at Vall d'Hebron Research Institute (VHIR), Dr. Xavier Montalban, talks about the green light from the health authorities to market Sativex in Spain, a drug derived from cannabis for the treatment of spasticity in multiple sclerosis patients. Twitter LinkedIn Facebook Whatsapp
